Factors associated with genital human papillomavirus infection among adult females in the United States, NHANES 2007–2010

BMC Research Notes

Glenn Mills¹  Hannah Taylor¹  Lihong Liu¹  Srinivas Devarakonda¹  Runhua Shi¹ 

[1] Department of Medicine, Feist-Weiller Cancer Center, LSU Health Shreveport, Shreveport, LA, USA

关键词: Survey;    Prevalence Ratio;    Sexual behaviors;    Human Papillomavirus;   

Others  :  1130354
DOI  :  10.1186/1756-0500-7-544

 received in 2014-04-23, accepted in 2014-08-12,  发布年份 2014

【 摘 要 】

Background

Patients with human papillomavirus (HPV) infection are at risk of developing cancer later in their life. Current research estimates the prevalence of genital HPV infection and explores the factors that are associated with the infection.

Findings

The National Health and Nutrition Examination Survey 2007–2010 was used in this research study. The study population included females in the United States aged 18–59 years. The weighted prevalence of HPV infection was 41.9%. An estimated 59.4% of non-Hispanic black females had HPV infection. In a multivariate analysis, number of sexual partners, race, age, education level, marital status, income, smoking, and insurance status were associated with HPV infection. HPV infection was 5.77 times more likely for women with >11 sexual partners compared to women with 0–1 partners. Non-Hispanic black females were 1.87 times more likely to have HPV infection compared to non-Hispanic white females. Participants with only a high school degree had a 58% increased prevalence compared to college-educated women. Uninsured women had a 39% increased prevalence compared to those with insurance.

Conclusion

This study found that 41.9% of U.S. females aged 18–59 years tested positive for genital HPV infection. We determined that individuals with more sexual partners, with a lower education level, with non-Hispanic black race, and with no insurance were the populations at greatest risk. It is necessary to continue monitoring the prevalence of this infection in the general population to provide a basis for effective treatment and prevention in the target populations.

【 授权许可】

   
2014 Shi et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Human Papillomavirus (HPV) Vaccines. [http://www.cancer.gov/cancertopics/factsheet/prevention/HPV-vaccine webcite]
• [2]Hariri S, Unger ER, Sternberg M, Dunne EF, Swan D, Patel S, Markowitz LE: Prevalence of genital human papillomavirus among females in the United States, the National Health And Nutrition Examination Survey, 2003–2006. J Infect Dis 2011, 204(4):566-573.
• [3]CDC: Human Papillomavirus–Associated Cancers — United States, 2004–2008. MMWR Morb Mortal Wkly Rep 2012, 61(15):630-632.
• [4]Basic Information about HPV-Associated Cancers. [http://www.cdc.gov/cancer/hpv/basic_info/ webcite]
• [5]Baseman JG, Koutsky LA: The epidemiology of human papillomavirus infections. J Clin Virol 2005, 32(Suppl 1):S16-24.
• [6]Gillison ML, Chaturvedi AK, Lowy DR: HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer 2008, 113(10 Suppl):3036-3046.
• [7]Cervical Cancer Statistics. http://www.cdc.gov/cancer/cervical/statistics/ webcite
• [8]Questionnaires, Datasets, and Related Documentation. http://www.cdc.gov/nchs/nhanes/nhanes_questionnaires.htm webcite
• [9]Johnson CL, Paulose-Ram R, Ogden CL e: National Health and Nutrition Examination Survey: Analytic guidelines, 1999–2010. National Center for Health Statistics. Vital Health Stat 2 2013, 2(161):1-15.
• [10]Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, Markowitz LE: Prevalence of HPV infection among females in the United States. JAMA 2007, 297(8):813-819.
• [11]Steinau M, Swan DC, Unger ER: Type-specific reproducibility of the Roche linear array HPV genotyping test. J Clin Virol 2008, 42(4):412-414.
• [12]Onyekwuluje JM, Steinau M, Swan DC, Unger ER: A real-time PCR assay for HPV52 detection and viral load quantification. Clin Lab 2012, 58(1–2):61-66.
• [13]Gravitt PE, Peyton CL, Alessi TQ, Wheeler CM, Coutlee F, Hildesheim A, Schiffman MH, Scott DR, Apple RJ: Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000, 38(1):357-361.
• [14]Sanders AE, Slade GD, Patton LL: National prevalence of oral HPV infection and related risk factors in the U.S. adult population. Oral Dis 2012, 18(5):430-441.
• [15]Korn E,B,G: Analysis of Health Surveys. New York, NY: Wiley; 1999.
• [16]Casella G, Berger R: Statistical Inference. Duxbury: Pacific Grove, CA; 1990.
• [17]RTI: SUDAAN Language Manual, Volumes 1 and 2, Release 11. First Edition edition. Research Triangle Park, NC: Research Triangle Institute; 2012.
• [18]Unger ER, Steinau M, Lin JMS, Patel SS, Swan DC: Impact of HPV Assay on Observed Population Prevalence. Diagn Mol Pathol 2011, 20(2):101-104.
• [19]Castle PE, Gravitt PE, Solomon D, Wheeler CM, Schiffman M: Comparison of linear array and line blot assay for detection of human papillomavirus and diagnosis of cervical precancer and cancer in the atypical squamous cell of undetermined significance and low-grade squamous intraepithelial lesion triage study. J Clin Microbiol 2008, 46(1):109-117.
• [20]Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, Bruni L, Tortolero-Luna G, Kjaer SK, Munoz N: Epidemiology and Natural History of Human Papillomavirus Infections and Type-Specific Implications in Cervical Neoplasia. Vaccine 2008, 26:K1-K16.
• [21]de Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Munoz N, Bosch FX: Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007, 7(7):453-459.
• [22]Garcia-Pineres AJ, Hildesheim A, Herrero R, Trivett M, Williams M, Atmetlla I, Ramirez M, Villegas M, Schiffman M, Rodriguez AC, Burk RD, Hildesheim M, Freer E, Bonilla J, Bratti C, Berzofsky JA, Pinto LA: Persistent human papillomavirus infection is associated with a generalized decrease in immune responsiveness in older women. Cancer Res 2006, 66(22):11070-11076.
• [23]Finer LB: Trends in premarital sex in the United States, 1954–2003. Public Health Rep 2007, 122(1):73-78.
• [24]Arbyn M, de Sanjose S, Saraiya M, Sideri M, Palefsky J, Lacey C, Gillison M, Bruni L, Ronco G, Wentzensen N, Brotherton J, Qiao YL, Denny L, Bornstein J, Abramowitz L, Giuliano A, Tommasino M, Monsonego J: EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease. Int J Cancer 2012, 131(9):1969-1982.
• [25]Applebaum KM, Furniss CS, Zeka A, Posner MR, Smith JF, Bryan J, Eisen EA, Peters ES, McClean MD, Kelsey KT: Lack of association of alcohol and tobacco with HPV16-associated head and neck cancer. J Natl Cancer Inst 2007, 99(23):1801-1810.
• [26]Marek E, Dergez T, Rebek-Nagy G, Szilard I, Kiss I, Ember I, Gocze P, D’Cruz G: Effect of an educational intervention on Hungarian adolescents’ awareness, beliefs and attitudes on the prevention of cervical cancer. Vaccine 2012, 30(48):6824-6832.
• [27]Markowitz LE, Hariri S, Lin C, Dunne EF, Steinau M, McQuillan G, Unger ER: Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003–2010. J Infect Dis 2013, 208(3):385-393.
• [28]Ratanasiripong NT: A Review of Human Papillomavirus (HPV) Infection and HPV Vaccine–Related Attitudes and Sexual Behaviors among College-Aged Women in the United States. J Am Coll Health 2012, 60(6):461-470.
• [29]Pourat N, Jones JM: Role of insurance, income, and affordability in human papillomavirus vaccination. Am J Manag Care 2012, 18(6):320-330.